Using tiny particles to kill cancer cells and boost the immune response
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
This study is testing tiny particles that can help kill cancer cells and boost your immune system to fight tumors, aiming to provide a safer and more effective treatment for people with tough-to-treat cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10840314 on NIH RePORTER |
What this research studies
This research focuses on developing ultrasmall nanoparticles that can directly induce cancer cell death while enhancing the body's immune response against tumors. By utilizing these specialized particles, the study aims to overcome the limitations of traditional cancer treatments, which often come with significant side effects. The approach involves using nanoparticles that can disrupt cancer cell signaling and promote cell death without relying on toxic drugs. This innovative method seeks to improve treatment outcomes for patients with difficult-to-treat cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hard-to-treat cancers who may benefit from novel therapeutic strategies.
Not a fit: Patients with early-stage cancers or those who do not have a significant immune response may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic cancer treatments that enhance the immune system's ability to fight tumors.
How similar studies have performed: Other research has shown promise in using nanoparticles for cancer treatment, indicating that this approach could be a viable and innovative strategy.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Bradbury, Michelle S — Weill Medical Coll of Cornell Univ
- Study coordinator: Bradbury, Michelle S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.